Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. - Wikidata - awgldk - TriplyDB

Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis.

Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis.

http://www.wikidata.org/entity/Q42515392

about

The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis.Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure New perspectives of biomarkers for the management of chronic hepatitis B.Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy.Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B.Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?The evolving epidemiology of hepatocellular carcinoma: a global perspective.Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma.Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analogue treatment.High-dose tenofovir is not effective in suppressing hepatitis B virus replication in patients with hepatocellular carcinoma progression: a preliminary result The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk - a cohort study of 44 494 subjects.Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics.Intermediate-stage hepatocellular carcinoma patients with a high HBV-DNA load may benefit from postoperative anti-hepatitis B virus therapy.Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.The risk of hepatocellular carcinoma is decreasing after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy.Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α.Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients.Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B.Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.Management of chronic hepatitis B in severe liver disease.Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy.Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis.Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis.Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study.High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases.FIB-4 index for assessing the prognosis of hepatocellular carcinoma in patients with Child-Pugh class A liver function.

P2860

Q28075923-F7473953-BB03-43EB-89F1-4E591792B3DB Q30391932-FF9C4453-21B5-41D4-85C9-E07B13B56D2C Q33872964-AECF4A47-A5AD-41E9-A98B-E7F6E6992988 Q35473087-960B83BC-B89F-42BE-A0CB-B98FA8BE51B1 Q35840984-F153D4F4-73C4-4543-91CD-E6B2CBA7F257 Q37358592-B0194505-A3D8-4ED5-9CCD-3912D7829442 Q37606546-2C83AAD1-1AF6-400F-B627-E396BEF08F41 Q37629064-761225FD-C540-4296-9F9F-27FB7DA160E4 Q38100847-DE19B4CA-41E3-4F68-BBD2-59FE06EAD2D7 Q38303237-37BE39BF-2F65-4921-B809-B91C7D060DED Q38397998-254AB51F-447C-442D-AE51-5877456BF356 Q38545840-FE2B0ADF-20EB-4E6B-869A-009DF13F4552 Q38596871-B63D243A-9FA3-44FC-98F6-02C3A771BF40 Q38630002-FE667F29-6613-41EB-84F4-E9ECCFC2FD58 Q38634991-26E3C825-6C5F-4015-A4D5-31F17B7EEFE1 Q38655765-71FCF27E-D56D-45B1-97A7-D8906D58970B Q38815530-CB52B446-C3E9-4A15-A684-CA3872415ADA Q38940522-456B9E88-62D5-408B-8188-07AB771AF8BB Q39136809-A6673014-680E-4AEE-8434-3D900787101F Q40107680-F6B9C8DF-AA36-40C3-9D8A-4C6D55015329 Q40151821-C5165531-61A4-4300-AB78-7F27490A9C33 Q40157059-2D4F1570-B769-414A-870B-69DB4B04FF6D Q40341578-84F443DD-F5C2-4BD3-84BF-8223F5304233 Q40557516-B625BC25-186D-469A-B7B3-EC6B32894A4B Q40612110-BB825B45-44C1-4CEF-8851-C831637191D3 Q40706734-65448206-CC09-4E48-9B91-93642F6FC195 Q41042019-69309338-6AAE-4671-81E9-094976A15FFF Q41583430-F4DC37E4-D0BC-4EA2-ABC3-ABF5A353F41D Q41619231-ED86C68B-8863-4F76-ABBA-3898BCFD7BC8 Q41673544-BC3DB417-A6B5-461A-AE51-BFF57C696C4B Q42121506-68B9F791-904E-4B6E-9488-951766CA90D2 Q42234354-7A59A35F-F31C-429F-BAC3-AB5BDE54D740 Q42262670-986F3E38-2468-4275-BF04-54532194958D Q42263840-E13C7D52-E629-43B4-839E-DBFE184A1F17 Q45326295-233F2F5E-7AFD-43EE-B0A4-A7CE8BE54EBC Q47231033-FCB97BF7-670E-4484-8A4E-CC925DB14803 Q47243952-1AB5CEF6-E78E-4C7F-8844-65F5B8C3D91A Q51261488-5DB91162-C443-4853-BD0A-F6554056C1A9 Q51283174-86086F10-ECBB-49A5-AE55-ECA054FE0B25 Q53627290-6ED4BE7C-7723-4B1F-9ED0-8B06D98D4B1E

P2860

Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis.

http://www.wikidata.org/entity/Q42515392

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Effect of nucleos

@nl

Effect of nucleos(t)ide analog ...... : a propensity score analysis.

@en

type

label

Effect of nucleos

@nl

Effect of nucleos(t)ide analog ...... : a propensity score analysis.

@en

prefLabel

Effect of nucleos

@nl

Effect of nucleos(t)ide analog ...... : a propensity score analysis.

@en

P1433

Q42515392-633D39D6-A700-441C-A68A-B621D4C47396

P1476

Q42515392-ABFDF1B8-DF6A-4358-B196-09DF92743C77

P2093

Q42515392-02699549-4119-4B4D-A512-C230088EAF84

Q42515392-09779300-C3AF-4351-BB2A-2AD52B70C3B9

Q42515392-178FC5E0-B542-4AE7-AE80-0B887C7741CF

Q42515392-1A27D58F-3839-48CD-812B-F44082E8E252

Q42515392-32A51E07-E2E1-491B-A47C-C62389A3B9FF

Q42515392-71AB76CF-A0F0-4303-99EB-C0996E9763C3

Q42515392-90927F88-66B7-4ED0-9E9A-81AB38B2054C

Q42515392-9183D47E-BD46-4573-8A76-E580F4CF297D

Q42515392-AE2FDB64-9D67-400E-B903-1225CF83AA1F

Q42515392-B3019A71-617C-436F-BE1C-DA72DB40C679

P304

Q42515392-49E0DEE8-030F-4AFC-B63D-E01464171765

P31

Q42515392-BE1F7314-CACC-41CE-A668-D5A29CDA56BF

P356

Q42515392-EFF44D37-A536-4B93-94E2-86510C140A09

P433

Q42515392-1766CF64-2465-457F-A962-0BD73170E036

P478

Q42515392-9EC3FC07-4B99-4940-A1E3-92A144CAFDA0

P577

Q42515392-58EDD21D-7611-47E2-AAA3-8EA4A9ABA13D

P698

Q42515392-4F4DF02C-603C-4652-800C-BDF9DA1B44D2

P356

J.JHEP.2012.10.025

P1433

Journal of Hepatology

P1476

Effect of nucleos(t)ide analog ...... : a propensity score analysis.

@en

P2093

Akira Kanamori

http://www.w3.org/2001/XMLSchema#string

Hidenori Toyoda

http://www.w3.org/2001/XMLSchema#string

Junko Tanaka

http://www.w3.org/2001/XMLSchema#string

Kenta Yamamoto

http://www.w3.org/2001/XMLSchema#string

Makoto Tanikawa

http://www.w3.org/2001/XMLSchema#string

Satoshi Yasuda

http://www.w3.org/2001/XMLSchema#string

Seiki Kiriyama

http://www.w3.org/2001/XMLSchema#string

Takashi Kumada

http://www.w3.org/2001/XMLSchema#string

Takurou Niinomi

http://www.w3.org/2001/XMLSchema#string

Toshifumi Tada

http://www.w3.org/2001/XMLSchema#string

P304

427-433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JHEP.2012.10.025

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23123221

http://www.w3.org/2001/XMLSchema#string